With regard to genetic abnormalities, the incidence of CBF leukemia was significantly lower in e/s‐AML patients as compared with young patients (7.1% vs 14.7%, P = .013 for RUNX1‐RUNX1TI and 2.6% vs 7.4%, P = .038 for CBFβ‐MYH11). Here, RUNX1 is linked to leukemia.